User profiles for Franco Maggiolo
 | Franco MaggioloASST Papa Giovanni XXIII Verified email at asst-pg23.it Cited by 11254 |
[HTML][HTML] Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection
Background Dolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was
recently approved in the United States for the treatment of human immunodeficiency virus …
recently approved in the United States for the treatment of human immunodeficiency virus …
Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study
A Castagna, F Maggiolo, G Penco… - The Journal of …, 2014 - academic.oup.com
Background. The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human
immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant …
immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant …
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and …
…, A Di Biagio, G Di Perri, A Gori, F Maggiolo… - The Lancet, 2019 - thelancet.com
Background Effective two-drug regimens could decrease long-term drug exposure and toxicity
with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy and …
with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy and …
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose …
J van Lunzen, F Maggiolo, JR Arribas… - The Lancet infectious …, 2012 - thelancet.com
Background Dolutegravir (S/GSK1349572) is a new HIV-1 integrase inhibitor that has antiviral
activity with once daily, unboosted dosing. SPRING-1 is an ongoing study designed to …
activity with once daily, unboosted dosing. SPRING-1 is an ongoing study designed to …
Cytomegalovirus coinfection is associated with an increased risk of severe non–AIDS-defining events in a large cohort of HIV-infected patients
…, A De Luca, M Moioli, F Maggiolo… - The Journal of …, 2015 - academic.oup.com
Background Chronic cytomegalovirus (CMV) infection has been associated with immunosenescence
and immunoactivation in the general population. In human immunodeficiency virus …
and immunoactivation in the general population. In human immunodeficiency virus …
Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors
F Maggiolo, L Ravasio, D Ripamonti… - Clinical infectious …, 2005 - academic.oup.com
Background . This prospective study verified the effect of adherence on the risk of virologic
failure. Methods . At enrollment in the study, a total of 543 patients who were following a …
failure. Methods . At enrollment in the study, a total of 543 patients who were following a …
One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects
…, L Sighinolfi, A Gori, F Suter, F Maggiolo - Patient preference …, 2010 - Taylor & Francis
Objective: The aim of the ADONE (ADherence to ONE pill) study was to verify the effect of a
reduced number of pills on adherence and quality of life (QoL) in HIV-infected patients on …
reduced number of pills on adherence and quality of life (QoL) in HIV-infected patients on …
Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3-or 4-drug regimen for maintaining virologic suppression in adults …
…, C Galera, L Hocqueloux, F Maggiolo… - Clinical Infectious …, 2023 - academic.oup.com
Background In TANGO, switching to dolutegravir/lamivudine (DTG/3TC) demonstrated long-term
noninferior efficacy vs continuing tenofovir alafenamide–based regimens in treatment-…
noninferior efficacy vs continuing tenofovir alafenamide–based regimens in treatment-…
Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C
E Minola, D Prati, F Suter, F Maggiolo… - Blood, The Journal …, 2002 - ashpublications.org
Before the introduction of hepatitis C virus (HCV) screening for blood donors, the risk of
acquiring HCV infection as a result of a transfusion was about 10%. The aim of this study was to …
acquiring HCV infection as a result of a transfusion was about 10%. The aim of this study was to …
Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI-or PI-treated patients
F Maggiolo, M Airoldi, HD Kleinloog, A Callegaro… - HIV clinical …, 2007 - Taylor & Francis
Background: The effect of adherence on the risk of virologic failure and mutations selection
was verified in a prospective study. Method: At baseline, all patients had a viral load (VL) <50 …
was verified in a prospective study. Method: At baseline, all patients had a viral load (VL) <50 …